TANDEM DIABETES CARE INC (TNDM)
CIK 1438133 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 69.6M shares as of Aug 3, 2026 (10-Q). Share count fell from 50.2M to 10.1M between Jul 24, 2017 and Oct 23, 2017, a pattern consistent with a reverse split (roughly 1-for-5); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Self-funding
generates cash
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Common Stock Warrant Expiring March2027 | 193,788 | $23.5 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 194,788 underlying shares, as reported Sep 30, 2022 (10-Q).
Reported exercise price: $73.73 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 69.8M = 69.6M O/S + 194,788 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Convertible Senior Notes Due 2029 | $316.3M | — | $34.56 | 1.5% | ~9.2M sh |
| Convertible Senior Notes Due 2032 | $300.0M | — | $36.99 | 0% | ~8.1M sh |
If every note above converted at its tagged price: ~17.3M new shares on 69.6M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 69.6M | Aug 3, 2026 |
| + Common Stock Warrant Expiring March2027 (if exercised) | 193,788 | Jun 30, 2026 |
| + Convertible Senior Notes Due 2029 (if fully converted) | 9.2M | Jun 30, 2026 |
| + Convertible Senior Notes Due 2032 (if fully converted) | 8.1M | Jun 30, 2026 |
| Fully diluted estimate | 87.0M | +25.1% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 1 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full TNDM workspace